In:
Radiation Oncology Journal, Korean Society for Therapeutic Radiology and Oncology, Vol. 40, No. 1 ( 2022-03-31), p. 20-28
Abstract:
Purpose: This study aimed to determine the correlation between protein induced by vitamin K absence or antagonist-II (PIVKA-II) and stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC). Materials and Methods: Sixty-one patients received SBRT between 2015 and 2020 with a median dose of 48 Gy (range, 39 to 60 Gy) with a median of 4 fractions. Changes in tumor markers before and after SBRT were analyzed. Results: The median follow-up period was 31 months (range, 12 to 64 months). The estimated 2-year in-field failure-free survival, progression-free survival (PFS), and overall survival rates were 82.0%, 39.3%, and 96.7%, respectively. Patients with decreased PIVKA-II levels through SBRT had significantly few in-field failures (p = 0.005). Patients with PIVKA-II levels of ≤25 mAU/mL after SBRT had significantly long PFS (p = 0.004). Conclusion: PIVKA-II could be a useful surrogate marker for response or survival outcomes in patients with localized HCC receiving SBRT.
Type of Medium:
Online Resource
ISSN:
2234-1900
,
2234-3156
DOI:
10.3857/roj.2021.00934
Language:
English
Publisher:
Korean Society for Therapeutic Radiology and Oncology
Publication Date:
2022
detail.hit.zdb_id:
2712565-8
Permalink